Stock Alert: Synlogic (SYBX) Climbing 18.58% in Pre-Market Hours for June 23

Equities Staff  |

Synlogic Inc (NASDAQ:SYBX) has already climbed $0.21 in early trading Thursday.

After closing the previous trading session at $1.13, Synlogic has moved 18.58% higher ahead of market open.

The company has increased 11.88% over the last 5 days.

Today could shape up to be an attractive day for Synlogic investors.

For technical charts, analysis, and more on Synlogic Inc visit the company profile.

Pre-market prices and movements as of 04:30:49 est.

About Synlogic Inc

Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic therapeutics that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.

To get more information on Synlogic Inc and to follow the company's latest updates, you can visit the company's profile page here: Synlogic Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content